Cargando…
High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing
BACKGROUND: Cystic fibrosis (CF) is a rare hereditary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recent therapies enable effective restoration of CFTR function of the most common F508del CFTR mutation. This shifts the unmet clinical need towar...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
European Respiratory Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885274/ https://www.ncbi.nlm.nih.gov/pubmed/36726369 http://dx.doi.org/10.1183/23120541.00495-2022 |
_version_ | 1784879900837019648 |
---|---|
author | Spelier, Sacha de Poel, Eyleen Ithakisiou, Georgia N. Suen, Sylvia W.F. Hagemeijer, Marne C. Muilwijk, Danya Vonk, Annelotte M. Brunsveld, Jesse E. Kruisselbrink, Evelien van der Ent, Cornelis K. Beekman, Jeffrey M. |
author_facet | Spelier, Sacha de Poel, Eyleen Ithakisiou, Georgia N. Suen, Sylvia W.F. Hagemeijer, Marne C. Muilwijk, Danya Vonk, Annelotte M. Brunsveld, Jesse E. Kruisselbrink, Evelien van der Ent, Cornelis K. Beekman, Jeffrey M. |
author_sort | Spelier, Sacha |
collection | PubMed |
description | BACKGROUND: Cystic fibrosis (CF) is a rare hereditary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recent therapies enable effective restoration of CFTR function of the most common F508del CFTR mutation. This shifts the unmet clinical need towards people with rare CFTR mutations such as nonsense mutations, of which G542X and W1282X are most prevalent. CFTR function measurements in patient-derived cell-based assays played a critical role in preclinical drug development for CF and may play an important role to identify new drugs for people with rare CFTR mutations. METHODS: Here, we miniaturised the previously described forskolin-induced swelling (FIS) assay in intestinal organoids from a 96-well to a 384-well plate screening format. Using this novel assay, we tested CFTR increasing potential of a 1400-compound Food and Drug Administration (FDA)-approved drug library in organoids from donors with W1282X/W1282X CFTR nonsense mutations. RESULTS: The 384-well FIS assay demonstrated uniformity and robustness based on coefficient of variation and Z’-factor calculations. In the primary screen, CFTR induction was limited overall, yet interestingly, the top five compound combinations that increased CFTR function all contained at least one statin. In the secondary screen, we indeed verified that four out of the five statins (mevastatin, lovastatin, simvastatin and fluvastatin) increased CFTR function when combined with CFTR modulators. Statin-induced CFTR rescue was concentration-dependent and W1282X-specific. CONCLUSIONS: Future studies should focus on elucidating genotype specificity and mode-of-action of statins in more detail. This study exemplifies proof of principle of large-scale compound screening in a functional assay using patient-derived organoids. |
format | Online Article Text |
id | pubmed-9885274 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | European Respiratory Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-98852742023-01-31 High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing Spelier, Sacha de Poel, Eyleen Ithakisiou, Georgia N. Suen, Sylvia W.F. Hagemeijer, Marne C. Muilwijk, Danya Vonk, Annelotte M. Brunsveld, Jesse E. Kruisselbrink, Evelien van der Ent, Cornelis K. Beekman, Jeffrey M. ERJ Open Res Original Research Articles BACKGROUND: Cystic fibrosis (CF) is a rare hereditary disease caused by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. Recent therapies enable effective restoration of CFTR function of the most common F508del CFTR mutation. This shifts the unmet clinical need towards people with rare CFTR mutations such as nonsense mutations, of which G542X and W1282X are most prevalent. CFTR function measurements in patient-derived cell-based assays played a critical role in preclinical drug development for CF and may play an important role to identify new drugs for people with rare CFTR mutations. METHODS: Here, we miniaturised the previously described forskolin-induced swelling (FIS) assay in intestinal organoids from a 96-well to a 384-well plate screening format. Using this novel assay, we tested CFTR increasing potential of a 1400-compound Food and Drug Administration (FDA)-approved drug library in organoids from donors with W1282X/W1282X CFTR nonsense mutations. RESULTS: The 384-well FIS assay demonstrated uniformity and robustness based on coefficient of variation and Z’-factor calculations. In the primary screen, CFTR induction was limited overall, yet interestingly, the top five compound combinations that increased CFTR function all contained at least one statin. In the secondary screen, we indeed verified that four out of the five statins (mevastatin, lovastatin, simvastatin and fluvastatin) increased CFTR function when combined with CFTR modulators. Statin-induced CFTR rescue was concentration-dependent and W1282X-specific. CONCLUSIONS: Future studies should focus on elucidating genotype specificity and mode-of-action of statins in more detail. This study exemplifies proof of principle of large-scale compound screening in a functional assay using patient-derived organoids. European Respiratory Society 2023-01-30 /pmc/articles/PMC9885274/ /pubmed/36726369 http://dx.doi.org/10.1183/23120541.00495-2022 Text en Copyright ©The authors 2023 https://creativecommons.org/licenses/by-nc/4.0/This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact permissions@ersnet.org (mailto:permissions@ersnet.org) |
spellingShingle | Original Research Articles Spelier, Sacha de Poel, Eyleen Ithakisiou, Georgia N. Suen, Sylvia W.F. Hagemeijer, Marne C. Muilwijk, Danya Vonk, Annelotte M. Brunsveld, Jesse E. Kruisselbrink, Evelien van der Ent, Cornelis K. Beekman, Jeffrey M. High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing |
title | High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing |
title_full | High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing |
title_fullStr | High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing |
title_full_unstemmed | High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing |
title_short | High-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing |
title_sort | high-throughput functional assay in cystic fibrosis patient-derived organoids allows drug repurposing |
topic | Original Research Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885274/ https://www.ncbi.nlm.nih.gov/pubmed/36726369 http://dx.doi.org/10.1183/23120541.00495-2022 |
work_keys_str_mv | AT speliersacha highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT depoeleyleen highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT ithakisiougeorgian highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT suensylviawf highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT hagemeijermarnec highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT muilwijkdanya highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT vonkannelottem highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT brunsveldjessee highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT kruisselbrinkevelien highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT vanderentcornelisk highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing AT beekmanjeffreym highthroughputfunctionalassayincysticfibrosispatientderivedorganoidsallowsdrugrepurposing |